Ongoing funded projects
Italian-French University, 2023, “Leonardo da Vinci” call, three-year jointly supervised doctoral scholarships, chapter 3, partnership with the University of Grenoble I, Joseph Fourier, Département de Pharmacochimie Moléculaire (Prof. Corinne Ravelet, coordinator), research : “Detection of a clinical biomarker using a biosensor based on nanoaggregate copper and aptamers”, 2023; Three projects for all disciplines were judged winners; MM PI;
She currently participates in the PNNR, Innovative Health Ecosystem, on the topic Nanotechnologies for Diagnosis and Therapy; in particular, the activity focuses on the theme: 2 Innovative analytical platforms for personalized, anticipated and low cost diagnostics” (UNIPI spoke 4 cluster);
Completed projects
Ministry of Health, Coordinator, “Abuse of immunotherapeutics in sport: development of a biosensor for myostatin inhibitors” (STAMULUMAB) 2020 Research Program on drugs, substances and medical practices that can be used for doping purposes in sporting activities (€62k) 18M; concluded on 06/30/2022;
Private Lender: PPM Services SA, A NOGRA Group company is incorporated in Switzerland, under reg. no CHE-420.383.918, whose registered office is in Morbio Inferiore; Affinity sensing for Nucleic acid analogues-based drugs; Research Agreement Manager, 2020;
EC Horizon 2020, ERA-NET – PhotonicSensing Transnational Call 2016, Project coordinator: “advanced PLAsmonic Biosensors ANalysis of nucleic acid (total project cost: 1050 k€, financed 556 k€ 36 M); end of 2021;
Ministry of Health, Coordinator, “Development of optical biosensors for the analysis of peptide hormones through molecularly imprinted polymers” acronym (MIPISA); 2018 Research Program on drugs, substances and medical practices that can be used for doping purposes in sporting activities (€120k) 18M;
University of Florence, Proposer: 2018 University call Request for funding for the purchase of an instrument aimed at research, Surface Plasmonic Resonance (SPR) for chemical research: broad-spectrum applications, Acquisition of SPR instrumentation (funding €74.6k );
Tuscany Region, POR FESR 2014-2020 – Action line 1.1.5.a3 – Aid for R&SI investments – FAR-FAS2014 call – PI Development of biophotonic sensors for the determination of GMOs in the environment, Acronym (SENSOGM) SENSOGM Project – (financing: €200k, 35M);
Private Lender bioMerieux Italia S.p.A. – (VAT number 01696821006) – headquarters Bagno a Ripoli, 50012 (FI) Italy, Head of the research agreement @ CSGI, 2017; Korea Institute of Science and Technology Forschungsgesellschaft mbH (“KIST Europe”), Saarbrücken, Germany, Research Agreement Manager @ CSGI, (12M), 2017; Sant’Anna Higher School of University Studies and Specialization (SSSA), Institute of Information Communication Technologies and Perception (TeCIP), April 2017 – Responsible for the @CSGI research agreement with the theme “Development of Nanoplasmonic Systems”;
European Union, 2015 (PI UNIFI-INNB project ULTRAPLACAD ULTRAsensitive PLAsmonic devices for early CAancer Diagnosis, grant agreement 633937), Horizon 2020 call “Personalising health and care (H2020-PHC-2014-two-stage)”, Topic: “Development of new diagnostic tools and technologies: in vitro devices, assays and platforms (PHC-10-2014)”, coordinator prof. G. Spoto (UNICT) (funding: 6 million euros; UNIFI-INBB: 100 thousand euros); Project evaluation: 15/15 Excellent in “excellence”, “impact” and “quality and efficiency of the implementation”; http://ultraplacad.eu;
Private financier, 2016 CdR s.r.l. (VAT number 04170450482 and C.F. 04170450482) – with headquarters in Lastra a Signa (FI), via degli Artigiani, 6, hamlet. Ginestra FI), Head of the @CSGI research agreement;
Italian-French University, 2013, Coordinator, “Leonardo da Vinci” call, Three-year joint doctoral scholarships, chapter 3, partnership with the University of Grenoble I, Joseph Fourier, Département de Pharmacochimie Moléculaire (Prof. Eric Peyrin). Three projects for all disciplines were judged winners; Title of the research “Development of affinity biosensors based on a new aptameric receptor, for the molecular diagnostics of Alzheimer’s disease” (funding: €60k) 36M;
World Antidoping Agency (WADA), 2010, PI, Scientific Research Grant 2010, “Detection of Hepcidin as a new Biomarker of Erythropoiesis Stimulators Abuse: A Pilot Study” (funding: US$150,000, pilot project, UNIFI US$50,000) 2010, 12M;
ARPA Foundation 2010, Pain Project, PI, Development of a DNA biosensor; Tuscany Region, PI, Program for Regional Research on Health 2009, title: “Minimally invasive microsystem for glucose monitoring in diabetic patients” (funding: €400k, UNIFI €80k); 36M;
Ministry of Health (external unit), “Genetic and pharmacological doping in sport. The race to use new doping agents and the development of new methods for detection. Training and information dedicated to athletes. Technicians, Managers, Students, Teachers”, 2009 (total funding: €80k);
World Antidoping Agency (WADA), 2008, Coordinator of the project “Affinity-Based Biosensing (ABBs) for gene doping detection: a pilot study”, within the “Scientific Research Grant -2008, Competition – topic C. Detection of Prohibited Substances/Methods : novel methodologies” (funding: 400,000 US$) 12M;
Ministry of Health, Coordinator of the project “Bioanalytical method based on biosensors for the new frontiers of doping: detection of exogenous proteins and genes” – 2005 Research Program on drugs, substances and medical practices that can be used for the purposes of doping in sports activities (funding : 80k€) 24M;
Private financier ElbaTech srl (VAT number 01298060490, Marciana (LI- Elba Island), via Roma, 10); Responsible (2003, Research Agreement for the implementation of a research entitled “Development, testing and optimization of unconventional DNA-chips, based on nanogravimetric systems” ElbaTech is a high-tech SME active in the field of electronics and sensors.
European Union PI, project “Growth of Large GaPO4 Single Crystals and their use for Special Sensor Applications”, acronym GAPOGROWTH, contract n° G5RD-CT-2002-00709 (UNIFI funding: €170k), 36M;
Ministry of Health, PI, Finalized research 2002 project “Cyclooxygenase-2 (COX2) inhibitors in the treatment of colorectal tumors” total funding: €196k); 24M;
Mobility financing
European Union 1991, “Strategies for in vivo sensing” Concerted action to carry out research activities 1 month at Pharmacia Biosensor AB, Uppsala, Sweden;